Please see full Prescribing Information for AREXVY. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...
For more information, you can refer to Boostrix’s prescribing information. Mild side effects that have been reported with Boostrix include: fever headache fatigue injection site reactions ...
Hosted on MSN10mon
What It’s Like to Have RSV as an Older AdultTalk to your doctor or visit www.AREXVY.com to learn more. Please see full Prescribing Information. You are encouraged to report vaccine adverse events to the US Department of Health and Human ...
GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY(Respiratory ...
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...
Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...
mResvia’s prescribing information indicates that the vaccine ... mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding ...
Please see full Prescribing Information for ZORYVE. ZORYVE is for topical use only and not for ophthalmic, oral, or intervaginal use. Arcutis cautions you that statements contained in this press ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback